Abstract
Abstract This review mainly focuses on the novel approaches that improve the safety and efficacy of immunotherapies, namely SLIT [alone or as pre-treatment of oral immunotherapy (OIT)], epicutaneous immunotherapy (EPIT), combination of anti-IgE into OIT or sublingual immunotherapy (SLIT) and introduction of hypoallergenic allergens by modifying native food products (boiling, baking, etc.) or manufacturing recombinant proteins. Among these proposals, some are clinically proven safe such as the use of anti-IgE while some are still under preclinical trials such as the use of some newly developed recombinant food protein allergens. What is certain is that more preclinical and clinical reviews and trials would be required on all these proposals before they could be maturely, safely, and effectively promoted in the clinical settings for patients’ use.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
